Generics Market Germany 2016-2018. Emergpharma report. 98 companies, nearly 1.000 molecules from 15 therapeutic segments assessed. Market evolution 2016-2018 in units and values.

1. Generics market
Germany 2016-2018

2. This report provides
information about the
following issues among others
How the market has evolved in values and units during the
period 2016-2018
Which companies have been and are the core players in
this period
Which companies have been the growth drivers in the
period and why
Which companies have lost market share in the period and
why
Strength and weaknesses of Top 20 players and 5 other
best performers
Which therapeutic segments are the most relevant in units
and values and how did they performed during the period
Which molecules are best sellers and which growth drivers
How does new comers affect to prices in the market
Which new molecules are expected and which companies
are ready to launch
Why Indian companies are consistently gaining market
share in the market
How has been competition between core players in the
most relevant therapeutic segments during the period

3. Methodology & Scope
Data: International panels and public
information
Filtering criteria:
• Phytomedicines not included
• Companies with residual generic sales excluded
• Diagnose / Vaccines / Veterinary products excluded
• Innovators excluded (no mature products considered)
Values: Euros
Units: Standard Units
Therapeutic criteria: ATC (ATC2 and ATC3)

4. Why buy
• Only updated report with data until 2018,
directed by J. Ignacio Díaz, a well reputed
professional with more than 20 years of
experience in the pharmaceutical sector
• 98 companies evaluated, about 1,000 molecules
from 15 therapeutic categories
• Structured, relevant and accurate information.
We do not write "to the weight" and we respect
the most important asset of our clients: time
• We offer a full refund guarantee, no questions
• We adapt to your needs: ad-hoc specific analysis
on demand

5. Index (I)
1. Executive Summary
2. Methodology and scope of the study
3. Inclusion / exclusion criteria
4. Global figures
4.1. Market evolution in euros
4.2. Market evolution in units (STUs)
4.3 Market split by therapeutic categories
4.4 Market split by companies (Top 20 + rest)
4.5 Market split by molecules (quartiles)

6. Index (II)
5. Analysis by companies
5.1 By size
5.1.1 Classification of companies by sales (values &
units). Analysis by quartiles
5.1.2. Top 20 companies: sales evolution in values
and units
5.1.3. Top 20 companies: MS evolution in values
and units
5.1.4. Individual analysis of the Top 20 companies
5.2 By performance
5.2.1. MS leadership in core therapeutic segments
5.2.2 Individual analysis of best performers not
included in 5.1
Individual profiles:
Top 20: Sandoz, Teva, Stada, Torrent, Zentiva, Aurobindo, Mylan, Sanofi, Menarini, KRKA, Pfizer,
Dermapharm, Aristo Pharma, Mundipharma, Sun Pharma, Neuraxpharma, Medac, Dr Reddys,
Glenmark, Fresenius
Non Top 20 best performers: INTAS, Microlabs, Stragen, Panpharma, Fair-Med

7. Index (III)
6. Analysis by therapeutic segments
6.1. MS by therapeutic segment in values. Changes
2016-2018
6.2 MS by therapeutic segment in units. Changes 2016-
2018
6.2. Growth analysis in values and units
6.4. Individual assessment of core therapeutics groups
• CNS (ATC N)
• Cardiovascular (ATC C)
• Antineoplastic and immunomodulating agents
(ATC L)
• Digestive system (ATC A02 A09, A1A)
• Antiinfectives (ATC J)
• Respiratory system (ATC R)
• Musculo-skeletal system (ATC M)
• Genito-urinary system and sex hormones (ATC G)
• Systemic hormonal preparations, excluding sex
hormones and insulins (ATC H)
• Blood and blood forming organs (ATC B)
• Dermatologic products (ATC D)
• Vitamins & minerals (ATC A11-A16)
• Antidiabetics (ATC A10)
• Sensory organs (ATC S)
• Antiparasitic products, insecticides and repellents
(ATC P)

8. Index (IV)
7. Analysis by molecule
7.1 Molecules best sellers and evolution
7.2 New molecules
7.3 Molecules stop selling
8. Pricing analysis
8.1 Average pricing evolution by category in stable molecules
(molecules with sales in 2016,2017 and 2018)
8.2 Prices evolution in new generics coming in 2017 and 2018
8.3 Prices elasticity to number of competitors. Analysis of 100
molecules
9. Expected new molecules and impact on market
9.1 By therapeutic group
9.2 Expected competition (intelligence review)

9. Purchase options
1. Basic module (single copy). Price: 1.200 €
Market evaluation & assessment by quartile
By companies (total figures)
By therapeutic segments (total figures)
By molecule (total figures)
2. In depth assessment. Price: 2.500 €
Top 20 top players & 5 additional best performers
individual profile
In detail evaluation of 15 therapeutic segments
Price-Elasticity to competitors analysis
Market trends / impact of new molecules
3. Ad-hoc analysis
Tailor made report to be budgeted individually on
demand

10. Purchase proccess
1. Report inquiry
Please email us for additional information (sources, warranty,
samples, etc.)
Your contact details will be treated confidentially
2. Product selection
We will personally contact you (email, TC) for clarification on
purchase procedure and additional information if required
Purchase order with the selected report (general, individual
profiles, ad-hoc) should be sent to us
3. Payment
Visa, Bank Transfer or Paypal. Our preferred payment method is
Paypal since it provides total guarantee to the customer
Payment details will be disclosed in personal contact
4. Report delivery
Once payment has been received, we deliver the report in hard copy
version plus USB pen drive. If required, an online version can be delivered
on demand for fast track

11. Refund guarantee
1. Paypal
We recommend Paypal because it provides a return guarantee to
the client in case the product does not conform to the agreed
upon
2. Visa / Bank transfer
Emergpharma offers an additional guarantee in case of Visa /
Transfer payment.
The client can request a partial printed version in advance and
will have a period of 7 days from the reception for confirming
the purchase or return the product. No reproduction of the
material will be authorized. Once the purchase is confirmed, the
digital version will be provided to the client as well as the
remaining part of the hard copy.
Client can also request samples before purchase to ensure the
quality is according to expectations.

12. Contact details
investments.consulting@emergpharmalinks.com
ATT: Mr. Jose Ignacio Díaz
Head of Commercial Operations
Emergpharma
Linkedin profile:
https://www.linkedin.com/in/j-ignacio-diaz-
057a897a?lipi=urn%3Ali%3Apage%3Ad_flagship3_profil
e_view_base_contact_details%3BAq%2FtCuLZTbOLEWD
DvN9PAw%3D%3D

13. Graphics
Samples

14. -1,5% -1,0% -0,5% 0,0% 0,5% 1,0% 1
NOVARTIS (SANDOZ)
TEVA
STADA
TORRENT
ZENTIVA
AUROBINDO
MYLAN
MENARINI
SANOFI
KRKA
PFIZER
DERMAPHARM
ARISTO PHARMA
MUNDIPHARMA INT
SUN PHARMA
NEURAXPHARM
MEDAC
DR REDDYS LAB
GLENMARK
FRESENIUS
Rest of companies
MS growth 2016-2018
MS Growth in units MS Growth in values
Source: Emergpharma Pannel

15. Source: Emergpharma Pannel
CNS
28%
Cardiovascular
16%
Antineoplastic and
Immunomodulating
9%
Digestive
8%
Antiinfectives
8%
Respiratory
7%
Muscle-Skeletic
5%
Rest of categories
19%
Market by Core Therapeutics 2018 %€

16. Source: Emergpharma Pannel
-
500.000
1.000.000
1.500.000
2.000.000
2.500.000
3.000.000
3.500.000
4.000.000
2.016 2.017 2.018
Penetration of Imatinib generics 2016-2018 (units)
GLIVEC GENERICS

17. Source: Emergpharma Pannel
-
20.000.000
40.000.000
60.000.000
80.000.000
100.000.000
120.000.000
140.000.000
160.000.000
TORRENT Sales by therapeutics (€ 2016-2018)
2.018 2.017 2.016